SELPLG

Summary

SELPLG (selectin P ligand, HGNC:10722) is a protein-coding gene on chromosome 12q24.11, encoding P-selectin glycoprotein ligand 1 (Q14242). A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation.

This gene encodes a glycoprotein that functions as a high affinity counter-receptor for the cell adhesion molecules P-, E- and L- selectin expressed on myeloid cells and stimulated T lymphocytes. As such, this protein plays a critical role in leukocyte trafficking during inflammation by tethering of leukocytes to activated platelets or endothelia expressing selectins. This protein requires two post-translational modifications, tyrosine sulfation and the addition of the sialyl Lewis x tetrasaccharide (sLex) to its O-linked glycans, for its high-affinity binding activity. Aberrant expression of this gene and polymorphisms in this gene are associated with defects in the innate and adaptive immune response. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 6404 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 73 total
• GTEx eGene: eQTL in 5 tissues, sQTL in 2 (q < 0.05)
• Drug target: yes — 1 curated mechanism-of-action drug; 1 molecules with ChEMBL bioactivity
• Constraint (gnomAD): pLI 0.01 (LoF-tolerant), LOEUF 1.94 (unconstrained)
• MANE Select transcript: NM_003006
• Interaction hub: 1,798 STRING partners (top 9% of genes corpus-wide)
• Notable: 73 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10722
Approved symbol	SELPLG
Name	selectin P ligand
Location	12q24.11
Locus type	gene with protein product
Status	Approved
Aliases	PSGL-1, CD162
Ensembl gene	ENSG00000110876
Ensembl biotype	protein_coding
OMIM	600738
Entrez	6404

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

MANE Select: ENST00000550948

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 5: 1

ENST00000550948, ENST00000228463, ENST00000388962, ENST00000884614, ENST00000884615, ENST00000942795, ENST00001137659

RefSeq mRNA: 2 — MANE Select: NM_003006 NM_001206609, NM_003006

CCDS: CCDS31895, CCDS55881

Canonical transcript exons

ENST00000550948 — 2 exons

Exon	Start	End
ENSE00002370460	108633740	108633894
ENSE00002412834	108621895	108624312

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 99.06.

FANTOM5 (CAGE): breadth broad, TPM avg 27.1349 / max 751.8667, expressed in 629 samples.

Highest expression (Bgee): granulocyte, blood, leukocyte, mononuclear cell, monocyte.

Genetic regulation across tissues (GTEx eQTL / sQTL)

SELPLG is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 5 tissues and its splicing (sQTL) in 2 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

7 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells EBV-transformed lymphocytes	eqtl	9.4e-06	+0.23	12:108635557:G:A
Cells Cultured fibroblasts	eqtl	1.2e-04	+0.14	12:108636953:T:C
Skin Sun Exposed Lower leg	eqtl	7.7e-03	+0.09	12:108633232:T:C
Spleen	sqtl	8.7e-03	-2.83	12:108023141:A:G
Minor Salivary Gland	eqtl	2.4e-02	+0.61	12:109044445:C:T
Heart Left Ventricle	eqtl	2.4e-02	-0.37	12:108483335:G:C
Testis	sqtl	4.4e-02	-0.28	12:108949061:T:C

FANTOM5 promoters

7 alternative TSS:

Promoter ID	TPM avg	Samples expressed
133144	16.8007	582
133146	8.7738	558
133145	1.1284	309
133143	0.2010	77
133142	0.0969	61
133138	0.0871	49
133139	0.0469	17

Top tissues by expression

showing 100 of 286 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.06	gold quality
blood	UBERON:0000178	98.45	gold quality
leukocyte	CL:0000738	97.25	gold quality
mononuclear cell	CL:0000842	97.08	gold quality
monocyte	CL:0000576	97.06	gold quality
spleen	UBERON:0002106	94.18	gold quality
lymph node	UBERON:0000029	93.55	gold quality
inferior vagus X ganglion	UBERON:0005363	92.26	gold quality
type B pancreatic cell	CL:0000169	92.24	gold quality
periodontal ligament	UBERON:0008266	91.77	gold quality
vermiform appendix	UBERON:0001154	91.29	gold quality
bone marrow cell	CL:0002092	90.40	gold quality
caecum	UBERON:0001153	89.80	gold quality
vena cava	UBERON:0004087	89.17	gold quality
bone marrow	UBERON:0002371	88.96	gold quality
right lung	UBERON:0002167	88.42	gold quality
upper lobe of left lung	UBERON:0008952	88.03	gold quality
subthalamic nucleus	UBERON:0001906	87.57	gold quality
upper lobe of lung	UBERON:0008948	87.32	gold quality
olfactory bulb	UBERON:0002264	87.13	gold quality
ventral tegmental area	UBERON:0002691	87.07	gold quality
gall bladder	UBERON:0002110	86.49	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.24	gold quality
bone element	UBERON:0001474	86.23	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.04	silver quality
spinal cord	UBERON:0002240	85.79	gold quality
parotid gland	UBERON:0001831	85.23	silver quality
dorsal plus ventral thalamus	UBERON:0001897	84.30	gold quality
heart right ventricle	UBERON:0002080	83.90	silver quality
lung	UBERON:0002048	83.33	gold quality
endothelial cell	CL:0000115	82.99	silver quality
lateral nuclear group of thalamus	UBERON:0002736	82.75	gold quality
trabecular bone tissue	UBERON:0002483	82.38	gold quality
superior vestibular nucleus	UBERON:0007227	82.34	gold quality
cranial nerve II	UBERON:0000941	82.20	gold quality
medulla oblongata	UBERON:0001896	82.13	gold quality
lateral globus pallidus	UBERON:0002476	81.85	silver quality
thymus	UBERON:0002370	81.51	gold quality
decidua	UBERON:0002450	81.29	gold quality
midbrain	UBERON:0001891	81.03	gold quality
triceps brachii	UBERON:0001509	81.00	silver quality
substantia nigra pars compacta	UBERON:0001965	80.94	gold quality
nasal cavity epithelium	UBERON:0005384	80.68	silver quality
body of tongue	UBERON:0011876	80.57	silver quality
substantia nigra	UBERON:0002038	80.50	gold quality
right coronary artery	UBERON:0001625	80.46	gold quality
amniotic fluid	UBERON:0000173	80.37	gold quality
smooth muscle tissue	UBERON:0001135	79.68	gold quality
gluteal muscle	UBERON:0002000	79.61	silver quality
lower lobe of lung	UBERON:0008949	79.58	silver quality
diaphragm	UBERON:0001103	79.28	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.26	gold quality
layer of synovial tissue	UBERON:0007616	79.20	gold quality
peritoneum	UBERON:0002358	79.00	gold quality
omental fat pad	UBERON:0010414	79.00	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	78.86	silver quality
adipose tissue of abdominal region	UBERON:0007808	78.76	gold quality
prefrontal cortex	UBERON:0000451	78.68	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	78.43	silver quality
pons	UBERON:0000988	78.24	silver quality
small intestine	UBERON:0002108	78.11	gold quality
substantia nigra pars reticulata	UBERON:0001966	78.05	gold quality
cardia of stomach	UBERON:0001162	77.86	silver quality
corpus callosum	UBERON:0002336	77.64	gold quality
pericardium	UBERON:0002407	77.43	silver quality
tongue squamous epithelium	UBERON:0006919	77.21	gold quality
rectum	UBERON:0001052	77.11	gold quality
left uterine tube	UBERON:0001303	76.85	gold quality
tongue	UBERON:0001723	76.82	silver quality
hypothalamus	UBERON:0001898	76.80	gold quality
mucosa of transverse colon	UBERON:0004991	76.76	gold quality
tonsil	UBERON:0002372	76.63	gold quality
male germ cell	CL:0000015	76.53	silver quality
pharyngeal mucosa	UBERON:0000355	76.50	silver quality
pylorus	UBERON:0001166	76.48	gold quality
skeletal muscle tissue	UBERON:0001134	76.40	gold quality
pancreatic ductal cell	CL:0002079	76.23	silver quality
muscle tissue	UBERON:0002385	76.18	gold quality
descending thoracic aorta	UBERON:0002345	76.10	gold quality
palpebral conjunctiva	UBERON:0001812	76.00	gold quality
epithelium of nasopharynx	UBERON:0001951	75.99	gold quality
coronary artery	UBERON:0001621	75.72	gold quality
superficial temporal artery	UBERON:0001614	75.60	gold quality
apex of heart	UBERON:0002098	75.59	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	75.46	gold quality
amygdala	UBERON:0001876	75.33	gold quality
right adrenal gland cortex	UBERON:0035827	75.32	gold quality
left coronary artery	UBERON:0001626	75.29	gold quality
sperm	CL:0000019	75.28	silver quality
trachea	UBERON:0003126	75.21	gold quality
visceral pleura	UBERON:0002401	74.82	gold quality
left adrenal gland	UBERON:0001234	74.79	gold quality
globus pallidus	UBERON:0001875	74.78	silver quality
adipose tissue	UBERON:0001013	74.73	gold quality
connective tissue	UBERON:0002384	74.66	gold quality
eye	UBERON:0000970	74.61	gold quality
adrenal cortex	UBERON:0001235	74.61	gold quality
saphenous vein	UBERON:0007318	74.55	gold quality
thoracic aorta	UBERON:0001515	74.49	gold quality
right uterine tube	UBERON:0001302	74.42	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	20.16
E-MTAB-9801	yes	6.04
E-CURD-88	yes	4.71
E-CURD-112	yes	4.07
E-MTAB-7606	no	6159.87
E-CURD-120	no	40.15

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 70 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Corpus callosum	tissue	62.9
Lymph node	tissue	58.3	high
Spleen	tissue	54.4	medium
Thymus	tissue	48.6
Basal ganglia	tissue	47.2	high
Caudate putamen	tissue	47.2
Appendix	tissue	44.8	not detected
Cerebral cortex	tissue	42.6	medium
Frontal cortex	tissue	42.6
Amygdala	tissue	42.2
Retrosplenial and cingulate cortex	tissue	40.7
Ventral forebrain	tissue	39.9
Lung	tissue	38.4	medium
Somatosensory cortex	tissue	38.2
Occipital cortex	tissue	35.0
Entorhinal cortex	tissue	33.1
Medulla oblongata	tissue	32.0
Spinal cord	tissue	31.1
Hippocampal formation	tissue	31.1
Septum	tissue	29.5
Tonsil	tissue	28.7	medium
Thalamus	tissue	25.4
Hypothalamus	tissue	23.5
Substantia nigra	tissue	23.3
Urinary bladder	tissue	20.2	not detected
Bone marrow	tissue	19.9	low
Hippocampus	tissue	19.8	high
Olfactory bulb	tissue	19.7
Locus coeruleus	tissue	19.4
Midbrain	tissue	17.3
Pons	tissue	17.0
Adipose tissue	tissue	16.4	not detected
Gallbladder	tissue	15.9	not detected
Placenta	tissue	12.2	not detected
Choroid plexus	tissue	11.9
Small intestine	tissue	11.5	not detected
Nucleus accumbens	tissue	11.1
Retrosplenial cortex	tissue	11.0
Stomach 1	tissue	10.7	not detected
Smooth muscle	tissue	10.7	not detected
Colon	tissue	9.0	not detected
Cervix	tissue	8.6	not detected
Adrenal gland	tissue	8.6	medium
Putamen	tissue	8.2
Esophagus	tissue	8.1	not detected
Duodenum	tissue	8.1	not detected
Rectum	tissue	7.9	not detected
Fallopian tube	tissue	7.4	not detected
Cerebellum	tissue	7.0	high
Tongue	tissue	6.8
Salivary gland	tissue	6.6	not detected
Breast	tissue	6.5	low
Liver	tissue	6.1	not detected
Postcentral gyrus	tissue	5.6
Heart muscle	tissue	4.7	not detected
Skin 1	tissue	4.4	not detected
Parathyroid gland	tissue	4.1	not detected
Seminal vesicle	tissue	3.7	not detected
Endometrium 1	tissue	3.5	not detected
Pancreas	tissue	3.2	medium

Brain sub-regions (HPA Brain Atlas): detected in 185; highest nTPM — White matter (62.9), Lateral funiculus (white matter) (46.9), Nucleus gracilis (32.0), Nucleus rhomboideus (31.5), Cervical spinal cord, ventral horn (31.1).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2, NFATC1, NR1H3, TXK

miRNA regulators (miRDB)

Targeting SELPLG by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 37 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-4293	99.22	65.46	1263
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-1843	98.97	66.07	838
HSA-MIR-4802-5P	98.97	66.26	833
HSA-MIR-6894-5P	98.70	63.78	809
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-6873-5P	98.45	66.14	1417
HSA-MIR-6884-3P	98.05	65.32	750
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-4535	97.27	65.17	469
HSA-MIR-203B-5P	97.24	68.54	543
HSA-MIR-6718-5P	97.24	68.15	553
HSA-MIR-509-3-5P	97.21	67.74	1517
HSA-MIR-509-5P	97.21	67.90	1512

Functional genomics

gnomAD constraint: pLI 0.00764, LOEUF 1.94, missense Z 1.04 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000550948 — one region, missense o/e 0.91.

Literature-anchored findings (GeneRIF, showing 40)

• Comparison of PSGL-1 microbead and neutrophil rolling: microvillus elongation stabilizes P-selectin bond clusters (PMID:11916843)
• Human mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1, E-selectin for adhesive interactions with human vascular endothelium under flow conditions (PMID:11929779)
• G-CSF down regulates PSGL-1 expression on the surface of neutrophils in humans (PMID:11961238)
• Attachment of the PSGL-1 cytoplasmic domain to the actin cytoskeleton is essential for leukocyte rolling on P-selectin. (PMID:12036880)
• Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for herpes simplex virus type 2(cutaneous lymphocyte-associated antigen) (PMID:12189248)
• Binding of two anti-human (KPL1 and PL1) and two anti-mouse (4RA10 and 2PH1) PSGL-1 mAbs to synthetic peptides of N-terminus of human and mouse PSGL-1 was found to be independent of tyrosine sulfation. (PMID:12223514)
• The epitope recognized by the M-DC8 MAb is 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1) (PMID:12354382)
• increased PSGL-1 expression on granulocytes from allergic-asthmatic subjects resulted in increased leukocyte recruitment on P-selectin under flow conditions (PMID:12377939)
• PSGL-1 engagement induces tyrosine phosphorylation of Syk and SRE-dependent transcriptional activity. (PMID:12387735)
• Inhibitors of glycosylation alter HECA-452 expression on human cutaneous lymphocyte-associated antigen-positive T-cells and prevent T-cell tethering and rolling on selectins under shear stress. (PMID:12393521)
• Stimulation of eosinophils with eotaxin-2 converts PSGL-1-P-selectin-dependent stationary adhesion to CD18-mediated shear-resistant stable attachment. Blocking eosinophil-platelet interactions may combat thrombotic disorders in hypereosinophilia. (PMID:12529243)
• Anti-P-selectin glycoprotein ligand-1 (PSGL-1) antibodies dramatically block the recruitment of CD8+ cells in brain vessels of patients with multiple sclerosis (PMID:12595306)
• L-selectin binds with high affinity to the N-terminal region of PSGL-1 through cooperative interactions with three sulfated tyrosine residues and an appropriately positioned C2-O-sLex O-glycan. (PMID:12736247)
• atomic force microscopy and flow-chamber experiments show that increasing force first prolonged and then shortened the lifetimes of P-selectin complexes with P-selectin glycoprotein ligand-1 (PMID:12736689)
• Anaplasma phagocytophilum infected neutrophils showed reduced expression of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and L-selectin (CD62L) (PMID:12874338)
• results demonstrate that the PSGL-1 variable number of tandem repeat polymorphism is not a genetic risk factor for coronary heart disease (PMID:12879153)
• determination that PSGL-1 is an additional substrate for BACE1 (PMID:14507929)
• PSGL1 is not essential for E-selection promotion of growth inhibition and apoptosis of human and murine hematopoietic progenitor cells (PMID:14592840)
• PSGL-1, by mediating monocyte-platelet interactions, plays a major role in secondary monocyte tethering. (PMID:14615387)
• platelet-monocyte complex formation is mostly dependent on PSGL-1 (PMID:14678816)
• PSGL-1 and VLA-4 play an important role for leukocyte recruitment during intestinal inflammation. Therapeutic strategies designed to disrupt interactions mediated by PSGL-1 and/or VLA-4 may prove beneficial in treatment of chronic colitis. (PMID:15001428)
• core 2 beta1-6-N-glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 have roles in rolling on P-selectin (PMID:15026421)
• platelet P-selectin and microparticle PSGL-1 have roles in thrombus formation [review] (PMID:15059608)
• binding of E-selectin to PMNs in suspension also elicited coclustering of L-selectin and PSGL-1 that was signaled via mitogen-activated protein kinase. (PMID:15187162)
• The interaction of PSGL-1 with P-selectin (CD62P) mediates tethering, rolling, and weak adhesion of leukocytes (PMID:15217824)
• PSGL-1 interacts with CCL27 (CTACK/ILC/ESkine), a skin-associated chemokine that attracts skin-homing T lymphocytes (PMID:15466853)
• CLA and E-selectin are bound by T cells and have roles in skin inflammation [cutaneous lymphocyte-associated antigen, also called BE-2] (PMID:15488708)
• PG-M/versican binds to P-selectin glycoprotein ligand-1 and has a role in mediating leukocyte aggregation (PMID:15522894)
• Induced expression of cutaneous lymphocyte antigen on helper T cells determined a striking increase of rolling efficiency in inflamed brain venules. (PMID:15843584)
• immune response to alpha-streptococci may enhance expression on tonsillar T-cells in pustulosis palmaris et plantaris (PMID:15925831)
• A differential functional impact of N-glycosylation on C2GnT-1 and FucT-VII and disclose that a strongly reduced FucT-VII activity retains the ability to fucosylate PSGL-1 on the core2-based binding site(s) for the three selectins. (PMID:15926890)
• CLA is expressed in circulating mononuclear cells of patients with psoriasis (PMID:16024226)
• In conclusion, the C allele of the VNTR polymorphism in PSGL-1 is likely to be associated with PP-MS. (PMID:16039046)
• biophysical analysis of PSGL-1/P-selectin neutrophil adhesion (PMID:16100264)
• CD43 is a T-cell E-selectin ligand distinct from PSGL-1 which expands the role of CD43 in the regulation of T-cell trafficking. (PMID:16269612)
• Plasmacytoid dendritic cells are particularly potent inducers of cutaneous lymphocyte-associated antigen on HSV-reactive memeory CD4 T cells (PMID:16501095)
• 98% of CLA(+) effector memory T cells are resident in normal skin under resting conditions (PMID:16547281)
• rPSGL-Ig delays the aggregation process and increases the anti-aggregatory potency of GPIIb-IIIa antagonist (PMID:16633357)
• More than 50% of circulating CD4+CD25(high) regulatory T cells from both patients as well as healthy controls expressed cutaneous lymphocyte-associated antigen. (PMID:17181632)
• No significant association was found between PSGL-1 VNTR polymorphisms and in-stent restenosis. However, in patients with a family history of early CAD presence of PSGL-1 AB genotype might increase the risk of in-stent restenosis. (PMID:17221329)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Selplg	ENSMUSG00000048163
rattus_norvegicus	Selplg	ENSRNOG00000000699

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:106689) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 9 distinct phenotype terms.

Mouse phenotype (MP)	Records
impaired leukocyte tethering or rolling	3
increased neutrophil cell number	2
increased eosinophil cell number	2
increased leukocyte cell number	1
abnormal leukocyte adhesion	1
increased lymphocyte cell number	1
increased bleeding time	1
impaired neutrophil chemotaxis	1
abnormal chemokine secretion	1

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
CORO1C	protein-coding	23603
TMEM119	protein-coding	338773
MIR4496	ncRNA	100616240
ISCU	protein-coding	23479
SSH1	protein-coding	54434
SART3	protein-coding	9733
FICD	protein-coding	11153

Protein

Protein identifiers

P-selectin glycoprotein ligand 1 — Q14242 (reviewed: Q14242)

Alternative names: Selectin P ligand

All UniProt accessions (2): A0A0C4DFY0, Q14242

UniProt curated annotations — full annotation on UniProt →

Function. A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture. (Microbial infection) Acts as a receptor for enterovirus 71.

Subunit / interactions. Homodimer; disulfide-linked. Interaction with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Sulfation on Tyr-51 of PSGL1 is most important for high affinity L-selectin/SELL binding while P-selectin/SELP requires sulfation on Tyr-48. E-selectin/SELE binds with much lower affinity and requires the sLe(x) epitope, but apparently not tyrosine sulfation. Dimerization appears not to be required for P-selectin/SELP binding. Interacts with SNX20. Interacts with MSN and SYK; mediates the activation of SYK by SELPLG. Interacts with HAVCR1. (Microbial infection) Interacts with enterovirus 71 capsid proteins. (Microbial infection) Interacts with Staphylococcus aureus proteins SSL5 and SSL11; these interactions prevent SELPLG-mediated neutrophil rolling.

Subcellular location. Membrane.

Tissue specificity. Expressed on neutrophils, monocytes and most lymphocytes.

Post-translational modifications. Displays complex, core-2, sialylated and fucosylated O-linked oligosaccharides, at least some of which appear to contain poly-N-acetyllactosamine with varying degrees of substitution. Mainly disialylated or neutral forms of the core-2 tetrasaccharide, Galbeta1–>4GlcNAcbeta1–>6(Galbeta1–>3)GalNAcOH. The GlcN:GalN ratio is approximately 2:1 and the Man:Fuc ratio 3:5. Contains about 14% fucose with alpha-1,3 linkage present in two forms: One species is a disialylated, monofucosylated glycan, and the other, a monosialylated, trifucosylated glycan with a polylactosamine backbone. The fucosylated forms carry the Lewis antigen and are important for interaction with selectins and for functioning in leukocyte rolling. The modification containing the sialyl Lewis X glycan is on Thr-57. No sulfated O-glycans. Some N-glycosylation. Sulfation, in conjunction with the SLe(x)-containing glycan, is necessary for P- and L-selectin binding. High affinity P-selectin binding has a preferred requirement for the isomer sulfated on both Tyr-48 and Tyr-51, whereas L-selectin binding requires predominantly sulfation on Tyr-51 with sulfation on Tyr-48 playing only a minor role. These sulfations play an important role in L- and P-selectin-mediated neutrophil recruitment, and leukocyte rolling.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14242-1	1	yes
Q14242-2	2

RefSeq proteins (2): NP_001193538, NP_002997* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026195	PSGL-1	Family

UniProt features (56 total): repeat 12, mutagenesis site 8, modified residue 6, region of interest 5, sequence conflict 5, glycosylation site 4, sequence variant 4, compositionally biased region 2, topological domain 2, signal peptide 1, propeptide 1, chain 1, disulfide bond 1, splice variant 1, transmembrane region 1, turn 1, helix 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
1G1S	P-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH PSGL-1 PEPTIDE	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14242-F1	50.77	0.06

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Plasma proteins, Candidate cardiovascular disease genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6)

Type	Positions
Pyrrolidone carboxylic acid	42
Sulfotyrosine	46, 48, 51
Phosphothreonine	406
Phosphoserine	409

Disulfide bonds (1)

Type	Positions
Interchain	320

Glycosylation sites (4)

Type	Positions
O-linked (galnac…) threonine	57
N-linked (glcnac…) asparagine	65, 111, 302

Mutagenesis-validated functional residues (8)

Position	Phenotype
44	no effect on l-selectin binding nor neutrophil rolling.
46–52	no sulfation. almost complete loss of p-selectin binding. no effect on e-selectin binding.
46–51	no sulfation. almost complete loss of p-selectin binding. no effect on e-selectin binding.
46	binding l-selectin reduced by 20%, neutrophil recruitment reduced by 30%, and lymphocyte rolling reduced by 32%; when associated with f-48 …
48	binding l-selectin reduced by 20%, neutrophil recruitment reduced by 30%, and lymphocyte rolling reduced by 32%; when associated with f-46 …
51	binding l-selectin reduced by 86%, neutrophil recruitment reduced by 75% and, lymphocyte rolling reduced by 69%; when associated with f-46 …
57	no e- nor p-selectin binding, and very little neutrophil rolling. binding of l-selectin reduced by 91%; when associated with f-46; f-48 and …
320	no dimer formation. no effect on p-selectin binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 2; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

2 pathways:

ID	Pathway	Evidence
R-HSA-202733	Cell surface interactions at the vascular wall	curated
R-HSA-109582	Hemostasis	—

MSigDB gene sets: 251 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, ZHAN_LATE_DIFFERENTIATION_GENES_UP, MYOGENIN_Q6, GOBP_RESPONSE_TO_PEPTIDE, ENK_UV_RESPONSE_KERATINOCYTE_UP, GCANCTGNY_MYOD_Q6, MODULE_45, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, CAGCTG_AP4_Q5, GOBP_CELL_CELL_ADHESION, GOBP_CELLULAR_EXTRAVASATION, GOBP_LEUKOCYTE_MIGRATION, KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP, TGIF_01

GO Biological Process (7): cell adhesion (GO:0007155), leukocyte migration (GO:0050900), leukocyte tethering or rolling (GO:0050901), leukocyte adhesive activation (GO:0050902), cellular response to interleukin-6 (GO:0071354), signal transduction (GO:0007165), symbiont entry into host cell (GO:0046718)

GO Molecular Function (4): virus receptor activity (GO:0001618), signaling receptor binding (GO:0005102), receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (4): uropod (GO:0001931), plasma membrane (GO:0005886), membrane (GO:0016020), plasma membrane raft (GO:0044853)

Reactome top-level categories

1 top-level categories:

Category	Pathways
Hemostasis	1

GO top-level categories

29 GO namespaces:

Category	Terms
cellular process	2
cellular extravasation	2
immune system process	1
cell migration	1
leukocyte adhesion to vascular endothelial cell	1
leukocyte activation	1
response to interleukin-6	1
cellular response to cytokine stimulus	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
viral life cycle	1
symbiont entry into host	1
symbiont entry into host cell	1
exogenous protein binding	1
protein binding	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1
binding	1
cell trailing edge	1
plasma membrane bounded cell projection	1
membrane	1
cell periphery	1
cellular anatomical structure	1
plasma membrane	1
membrane raft	1
plasma membrane region	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 7 of 15 annotations. The rest are phylogenetic / computational / electronic (IEA).

7 experimentally-supported GO terms:

GO term	NS	Evidence
cellular response to interleukin-6	BP	direct assay
leukocyte migration	BP	direct assay
leukocyte tethering or rolling	BP	direct assay
plasma membrane	CC	direct assay
plasma membrane raft	CC	direct assay
uropod	CC	direct assay
receptor ligand activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,798 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SELPLG	SELP	P16109	966
SELPLG	SELE	P16111	890
SELPLG	SPN	P16150	821
SELPLG	SNX20	Q7Z614	819
SELPLG	HECA	Q9UBI9	815
SELPLG	GP1BA	P07359	802
SELPLG	FUT7	Q11130	775
SELPLG	SELL	P14151	749
SELPLG	F3	P13726	720
SELPLG	SIGLEC1	Q9BZZ2	699
SELPLG	CD40LG	P29965	693
SELPLG	CCR9	P51686	688
SELPLG	ITGB2	P05107	680
SELPLG	GLG1	Q92896	676
SELPLG	ICAM1	P05362	666

IntAct

Human interaction partners of SELPLG in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

5 partners by confidence:

Partner	Interaction type	MIscore	Records
SELP	direct interaction	0.800	5
SNX20	physical association	0.610	5
SELE	direct interaction	0.440	1
SELL	direct interaction	0.440	1
FLOT2	colocalization	0.380	2

BioGRID (13 interactions; top human partners by supporting records): TNIP1 (Affinity Capture-Western; 3 records), MAGEA1 (Two-hybrid; 2 records), MSN (Reconstituted Complex), PIK3R1 (Affinity Capture-Western), POLI (Reconstituted Complex), SELP (Affinity Capture-Western), SLC13A1 (PCA), TPST1 (Affinity Capture-Western), TPST2 (Affinity Capture-Western)

SIGNOR signaling

showing 2 of 3 signaling interactions:

A	Effect	B	Mechanism
SELPLG	up-regulates	SELP	binding
SELPLG	up-regulates	SELE	binding

Protein complexes (CORUM) (2)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

2 complexes by size:

Complex	Subunits	Members
★ MSN-SELPLG-SYK complex	3	MSN, SELPLG, SYK
★ SELP-SELPLG complex	2	SELPLG, SELP

Ligand–receptor pairs (CellPhoneDB) (3)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

3 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
SELP	ligand	Signaling by Selectin
SELE	ligand	Signaling by Selectin
SELL	ligand	Signaling by Selectin

Disease & clinical

Genetic variants

Variant evidence for SELPLG: 73 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.

ClinVar

73 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	15
Benign	4

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 18 predictions of 51):

Position(s)	Effect	Δscore	Sites
12:108624313–108624314	acceptor_loss	1.0000	5
12:108624313	acceptor_loss	0.9800
12:108633738–108633739	donor_loss	0.9800	5
12:108624325	acceptor_gain	0.8800
12:108633738	donor_loss	0.8600
12:108633751	donor_gain	0.8600
12:108625305	donor_gain	0.8500
12:108624326	acceptor_gain	0.8200
12:108631870	donor_gain	0.6000
12:108633735	donor_loss	0.6000

AlphaMissense

246 missense substitutions predicted likely pathogenic (of 2,616 scored), across 62 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M362	9	0.875	0.979
F410	8	0.951	0.995
S409	8	0.875	0.991
F334	8	0.843	0.962
E361	7	0.956	0.989
C364	7	0.955	0.986
C320	7	0.888	0.985
I365	7	0.881	0.994
D403	7	0.845	0.923
T406	6	0.818	0.910
I324	6	0.813	0.962
P412	6	0.723	0.800
V340	6	0.717	0.969
D404	6	0.667	0.715
L341	5	0.816	0.976
Y352	5	0.777	0.876
K318	5	0.776	0.880
V363	5	0.748	0.911
V317	5	0.719	0.790
C337	4	0.887	0.995

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Head and Neck Squamous Cell Carcinoma (TCGA)	favorable	0.000912

Disease associations

OMIM: gene MIM:600738 | disease phenotypes:

GWAS associations

4 associations:

Study	Trait	p-value
GCST010703_222	Brain morphology (MOSTest)	6e-13
GCST006585_2990	Blood protein levels	2e-12
GCST000713_3	Conduct disorder (symptom count)	3e-6
GCST002481_2	Acne (severe)	5e-6

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3301394 (PROTEIN-PROTEIN INTERACTION), CHEMBL4183 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the SELPLG protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

1 curated-mechanism drugs:

Drug	Modality	Max phase
NEIHULIZUMAB	Antibody	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 163 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1215923	BIMOSIAMOSE	2	163

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

46 measured of 47 human assays (47 total across all organisms); most potent 46 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
6-bromo-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylicacid	IC50	211 nM
2-(4-chlorophenyl)-3-hydroxy-6-(trifluoromethyl)quinoline-4-carboxylic acid	IC50	270 nM
2-(4-chlorophenyl)-3-hydroxy-6-(trifluoromethoxy)quinoline-4-carboxylic acid	IC50	4000 nM
2-(4-chlorophenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylicacid	IC50	4000 nM
2-(4-chlorophenyl)-3-hydroxy-6,8-dimethylquinoline-4-carboxylicacid	IC50	4900 nM
3-hydroxy-2-phenylquinoline-4-carboxylic acid	IC50	12000 nM
3-hydroxy-7,8-dimethyl-2-(4-(trifluoromethyl)phenyl)quinoline-4-carboxylic acid	IC50	32000 nM
6-bromo-2-(4-chlorophenyl)-3-hydroxy-8-methylquinoline-4-carboxylic acid	IC50	41000 nM
2-(4-bromophenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylicacid	IC50	56000 nM
2-(4-chlorophenyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid	IC50	130000 nM
8-bromo-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylicacid	IC50	132000 nM
5-Acetylamino-2-{2-[5-acetylamino-2-hydroxy-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yloxy]-3,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-4-yloxy}-4-hydroxy-6-(1,2,3-trihydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid	IC50	134000 nM
2-(4-chlorophenyl)-3-hydroxy-8-trifluoromethylquinoline-4-carboxylic acid	IC50	136000 nM
8-chloro-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylicacid	IC50	141000 nM
2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid	IC50	150000 nM
2-(4-chlorophenyl)-3-hydroxy-8-(thien-3-yl)quinoline-4-carboxylicacid	IC50	175000 nM
3-Hydroxy-2-(1-phenylethyl)-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic	IC50	175000 nM
3-hydroxy-7,8-dimethyl-2-(3-(trifluoromethoxy)phenyl)quinoline-4-carboxylic acid	IC50	200000 nM
2-(4-chlorophenyl)-3-hydroxy-8-methylquinoline-4-carboxylicacid	IC50	212000 nM
2-(4-chlorophenyl)-3-hydroxy-8-methyl-6-(trifluoromethoxy)-quinoline-4-carboxylic acid	IC50	225000 nM
2-(4-chlorophenyl)-3-hydroxy-6-phenylquinoline-4-carboxylic acid	IC50	230000 nM
3-hydroxy-7,8-dimethyl-2-(4-(trifluoromethoxy)phenyl) quinoline-4-carboxylic acid	IC50	240000 nM
3-hydroxy-2-(4-isopropylphenyl)-7,8-dimethylquinoline-4-carboxylic acid	IC50	250000 nM
2-(4-(diethylamino)phenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylic acid	IC50	250000 nM
3-Hydroxy-2-(1-phenylcyclopropyl)-7,8,9,10-tetrahydrobenzo-[h]quinoline-4-carboxylic Acid	IC50	250000 nM
2-(4-chlorophenyl)-3-hydroxy-8-isopropylquinoline-4-carboxylicacid	IC50	283000 nM
2-(4-chlorophenyl)-8-(dimethylaminophenyl)-3-hydroxyquinoline-4-carboxylic acid	IC50	300000 nM
8-sec-butyl-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylicacid	IC50	301000 nM
2-(3-chlorophenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylicacid	IC50	400000 nM
2-benzyl-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid	IC50	413000 nM
2-(4-chlorophenyl)-3-hydroxy-8-phenylquinoline-4-carboxylicacid	IC50	500000 nM
2-(4-chlorophenyl)-8-ethyl-3-hydroxyquinoline-4-carboxylicacid	IC50	525000 nM
3-hydroxy-7,8-dimethyl-2-p-tolylquinoline-4-carboxylic acid	IC50	1e+06 nM
3-hydroxy-2-(4-methoxyphenyl)-7,8-dimethylquinoline-4-carboxylic acid	IC50	1e+06 nM
3-hydroxy-7,8-dimethyl-2-(4-morpholinophenyl)quinoline-4-carboxylic acid	IC50	1e+06 nM
2-(4-chlorophenyl)-3-hydroxy-7-isopropylquinoline-4-carboxylicacid	IC50	1.5e+06 nM
3-hydroxy-7,8-dimethyl-2-phenylquinoline-4-carboxylic acid	IC50	1.5e+06 nM
2-(4-chlorophenyl)-3,6-dihydroxyquinoline-4-carboxylic acid	IC50	1.5e+06 nM
8-(4-carboxyphenyl)-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylic acid	IC50	1.5e+06 nM
2-(4-chlorophenyl)-3-hydroxy-8-(4-hydroxymethylphenyl)-quinoline-4-carboxylic acid	IC50	2e+06 nM
2-(4-chlorophenyl)-3-hydroxy-7-phenylquinoline-4-carboxylicacid	IC50	2e+06 nM
6-amino-2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylicacid	IC50	3e+06 nM
3-hydroxy-2-(4-hydroxyphenyl)-7,8-dimethylquinoline-4-carboxylicacid	IC50	3.5e+06 nM
2-(4-chlorophenyl)-3-hydroxyquinoline-4-carboxylic acid	IC50	4e+06 nM
2-[2-(3,4,5-Trihydroxy-6-{[2-(1-phenyl-ethylcarbamoyl)-benzoylamino]-methyl}-tetrahydro-pyran-2-yl)-acetylamino]-pentanedioic acid	IC50	5e+06 nM
(4R,5S)-5-[({[6-({[(1S)-1,3-dicarboxypropyl]carbamoyl}methyl)-3,4,5-trihydroxyoxan-2-yl]methyl}carbamoyl)amino]-2-{[(3S,4S,5S)-2-{[(2S,3S)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-{[(2S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate	IC50	2.5e+08 nM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases expression, increases expression	3
(+)-JQ1 compound	decreases expression	2
Atrazine	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	affects expression, increases methylation	2
Tretinoin	affects cotreatment, increases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
daidzein	affects cotreatment, affects expression	1
triphenyl phosphate	affects expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
daidzin	affects cotreatment, affects expression	1
arsenite	increases methylation	1
zinc chloride	increases expression	1
butyraldehyde	increases expression	1
ferrous sulfate	increases expression	1
zinc chromate	increases abundance, increases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
genistin	affects cotreatment, affects expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
Am 580	decreases expression	1
chromium hexavalent ion	increases expression, increases abundance	1
glycitein	affects cotreatment, affects expression	1
glycitin	affects expression, affects cotreatment	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Rosiglitazone	decreases expression	1
Sunitinib	decreases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3293895	Binding	Inhibition of PSEL/PSGL1 (unknown origin) interaction	Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies. — *J Med Chem*

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1G8	Abcam Jurkat SELPLG KO	Cancer cell line	Male
CVCL_F4QN	HyCyte HEK293T stable cell line for hSELPLG overexpression	Transformed cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for SELPLG across ~30M SureChEMBL compounds — explore on Sugi Predict.